In this issue:
Dacomitinib vs gefitinib in untreated EGFR+ NSCLC
Alectinib: new standard of care in untreated ALK+ NSCLC?
Consider adjuvant gefitinib in stage II/IIIA EGFR-mut lung cancer
Nintedanib improves survival in advanced MPM
Combination immunotherapy shows promise in MPM
First-line ceritinib active in advanced ALK-rearranged NSCLC
Maintenance pembrolizumab may benefit ES SCLC
Immunotherapy feasible in NSCLC and history of autoimmune disease
Inflammatory markers may predict for response to immunotherapy
Liquid biopsy: ctDNA detection shows potential in NSCLC
Please login below to download this issue (PDF)